Xyntha' Sales Exceed BDI Pharma’s Q1 Projections
Published: 20-May-2009
BDI Pharma, a wholesaler of biopharmaceutical products, has posted strong growth in sales of Wyeth’s XYNTHA Antihemophilic Factor (Recombinant) for the first quarter of 2009. Sales in the US exceeded BDI’s projections by 22% in Q1. XYNTHA is a Plasma-Free and Albumin-Free recombinant factor VIII product.
William Shirey, Executive VP of BDI, said: “The fact that our company's sales for XYNTHA have tracked twenty-two percent (22%) ahead of the results forecasted for the first fiscal quarter and continue to pace at an even greater rate thus far for Q2, reflects BDI's ability to assist its trade partners with the introduction of new products, the development of brand identity and the generation of vital market share.”
FDA approved XYNTHA controls and prevents bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia), and also used for surgical prophylaxis in patients with hemophilia A.
Delicious
Digg
Reddit
Stumble
Facebook
LinkedInNetwork Sites
Mail sent successfully
Suppliers To This Sector
Browse A-Z
Thomson Reuters
The World's Leading Source of Life Sciences Intelligent Information ...
Pharma IQ
Workshops, Conferences and Training Courses for Pharmaceutical Professionals ...
Parenteral Drug Association (PDA)
Pharmaceutical Information and Education Services ...
Nycomed
Contract Services ...
MHRA
The Medicines and Healthcare Products Regulatory Agency ...
Medilingua Translations
The Medical Translation Specialists ...
White Papers
Browse A-Z
Water Treatment
From the control room to the downstream processing area and with an eye on utilities servi ...
A Vaccinne Bioassay Case Study – A Successful Strategic Outsourcing Model
Increasingly, pharma and biotech firms are searching for new drivers of revenue and profit ...
USB HotStart-IT for Real Time PCR
USB® Products from Affymetrix have a long-standing reputation in the life science marketpl ...
Enabling Drug Delivery Deal Making
Transdermal drug delivery: Time for a closer look. To find out more download this free whi ...
Automating Training Control Processes to Comply with FDA Requirements
Well-managed training programs minimize the risk of non-compliance and improve product qua ...
TNO Pharma Services: From Discovery to the Clinic
Our kinetics & metabolism experts can help you select and further develop your candidate d ...
